Click on headlines below to download research

Licensing deal and R&D pipeline progress
NeuroVive Pharmaceutical | 05/10/2018

On 18 June 2018, NeuroVive announced that it had out-licensed a subset of compounds from its NVP015 programme (succinate prodrugs) to BridgeBio, a private…

KL1333 Ph I positive; rights issue oversubscribed
NeuroVive Pharmaceutical | 04/06/2018

On 27 April 2018, NeuroVive announced that the planned rights issue was oversubscribed (104%), delivering SEK78.5m in gross proceeds and funding the operations…

Bitesize briefing - NeuroVive Pharmaceutical
Bitesize briefing - NeuroVive Pharmaceutical | 24/04/2018

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of…

Rights issue to reach several R&D events
NeuroVive Pharmaceutical | 05/03/2018

NeuroVive’s planned rights issue (subject to approval at the EGM) is expected to bring in a minimum guaranteed amount of at least SEK55m (gross),…

Two new trials and likely out-licensing in 2018
NeuroVive Pharmaceutical | 14/12/2017

NeuroVive has made progress on multiple fronts over the past few months with both its core asset portfolio and non-core projects for out-licensing. Notable…

Executive Interview - NeuroVive Pharmaceutical
Executive Interview - NeuroVive Pharmaceutical | 29/11/2017

NeuroVive is a leader in mitochondrial medicine, with one project in clinical Phase II development for the prevention of moderate to severe traumatic brain…

R&D progress on track; new investor on board
NeuroVive Pharmaceutical | 25/08/2017

NeuroVive’s recent Q217 report described R&D activities progressing according to plan. The company is preparing for the next clinical studies…

Mitochondrial medicine specialist
NeuroVive Pharmaceutical | 29/06/2017

NeuroVive Pharmaceutical is a mitochondrial medicine specialist with a diversified asset portfolio. It employs a two-pronged strategy and has a portfolio…